Last $1,065 MXN
Change Today -38.00 / -3.45%
Volume 44.0
MDT* On Other Exchanges
Symbol
Exchange
New York
Mexico
Frankfurt
As of 4:09 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

medtronic inc (MDT*) Snapshot

Open
$1,065
Previous Close
$1,103
Day High
$1,065
Day Low
$1,065
52 Week High
12/22/14 - $1,103
52 Week Low
02/4/14 - $713.25
Market Cap
1.0T
Average Volume 10 Days
1.0K
EPS TTM
--
Shares Outstanding
984.3M
EX-Date
12/30/14
P/E TM
--
Dividend
$1.22
Dividend Yield
1.45%
Current Stock Chart for MEDTRONIC INC (MDT*)

medtronic inc (MDT*) Details

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group’s products include pacemakers; insertable cardiac monitors; implantable defibrillators; leads and delivery systems; ablation products; electrophysiology catheters; products for the treatment of atrial fibrillation; information systems for the management of patients with cardiac rhythm disease management devices; products to reduce surgical site infections; coronary and peripheral stents and related delivery systems; therapies for uncontrolled hypertension; endovascular stent graft systems; heart valve replacement technologies; cardiac tissue ablation systems; and open heart and coronary bypass grafting surgical products. The Restorative Therapies Group offers products for various areas of the spine; bone graft substitutes; biologic products; trauma, implantable neurostimulation therapies, and drug delivery systems for the treatment of chronic pain, movement disorders, obsessive-compulsive disorder, overactive bladder, urinary retention, fecal incontinence, and gastroparesis; products to treat conditions of the ear, nose, and throat; and systems that incorporate advanced energy surgical instruments. It also manufactures and sells image-guided surgery and intra-operative imaging systems. The Diabetes Group’s products include insulin pumps; continuous glucose monitoring systems; insulin pump consumables; and Web-based therapy management software solutions. The company serves hospitals, physicians, clinicians, and patients in approximately 140 countries. Medtronic, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

49,247 Employees
Last Reported Date: 06/20/14
Founded in 1949

medtronic inc (MDT*) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $774.9K
Executive Vice President and Group President ...
Total Annual Compensation: $724.9K
Executive Vice President and Group President ...
Total Annual Compensation: $675.1K
Chief Human Resources Officer and Senior Vice...
Total Annual Compensation: $781.7K
Compensation as of Fiscal Year 2014.

medtronic inc (MDT*) Key Developments

Medtronic, Inc.(NYSE:MDT) dropped from S&P 500 Value Index

Medtronic, Inc.(NYSE:MDT) dropped from S&P 500 Value Index

Medtronic, Inc. Announces FDA Approval and Commercial Launch of Two Additional Attain Performa Left Ventricular Quadripolar Leads

Medtronic, Inc. has announced the FDA approval and commercial launch of two additional Attain Performa left ventricular, or LV, quadripolar leads, which can be paired with the Medtronic Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators, or CRT-D, to treat patients with heart failure. The newest additions to the Attain Performa lead portfolio, the S-shape and Straight leads, are designed to accommodate patients' varying vessel sizes and curvatures to enhance successful lead placement. Quadripolar leads (leads with four electrodes) help physicians optimize cardiac resynchronization therapy, which uses an implantable device to improve the pumping efficiency of the heart. FDA approval for the additional quadripolar leads follows the August 2014 approval of the Attain Performa Model 4298 Dual Cant quadripolar lead. All three leads were studied in the multicenter Attain Performa Quadripolar Lead Clinical Study, involving more than 1,200 patients. Results demonstrate an excellent implant success rate (97.6%), and show that CRT with the Attain Performa family of LV quadripolar leads is associated with a low complication rate, and low, stable pacing capture thresholds (PCTs) through six months for all pacing polarities. The three Attain Performa lead shapes -Dual Cant Model 4298, Straight Model 4398 and S-Shape Model 4598 -were designed to accommodate various anatomies without compromising lead handling or stability. With 16 pacing configurations and shorter spacing between the two center electrodes, these quadripolar leads have been shown to reduce the incidence of phrenic nerve stimulation (PNS), a potential issue associated with CRT therapy that results in muscle twitching, hiccups or shortness of breath. Attain Performa leads also include steroid elution on all four electrodes for lower chronic pacing thresholds, which contribute to greater device longevity and reduce the likelihood of PNS. All three Attain Performa leads are compatible with the company's newest portfolio of CRT devices, the Viva Quad XT and Viva Quad S CRT-D systems. The Viva Quad XT CRT-D features the Medtronic-exclusive AdaptivCRT algorithm, which significantly improves heart failure patients' response rate to therapy by preserving normal heart rhythms and automatically adapting to patient needs, creating a customized therapy for each patient. AdaptivCRT is the only algorithm demonstrated to improve heart failure patients' response to the therapyiv (as compared to conventional biventricular therapy) and reduce the risk of atrial fibrillation, or AFv. The system also includes VectorExpress technology, an automated in-office test that reduces lead programming time to two minutes,vi and reveals clinically actionable information to help physicians select optimal pacing configurations for each patient. The Attain Performa Quadripolar Lead Clinical Study is a global trial that evaluated the safety and effectiveness of the Attain Performa leads. The study demonstrated a 97.6% implant success rate and the PNS complication-free rate was 99.7%. Steroid on all four electrodes resulted in low, stable PCTs through six months for all pacing polarities. The study enrolled 1,201 patients indicated for a CRT-D from approximately 130 centers across the world. All implanted patients were followed at one, three, six and every subsequent six months post-implant.

Medtronic, Inc. Receives FDA Approval and Launches Two New Cardiac Resynchronization Therapy Quadripolar Leads

Medtronic, Inc. announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa(R) left ventricular (LV) quadripolar leads, which can be paired with the Medtronic Viva(R) Quad XT and Viva(R) Quad S cardiac resynchronization therapy defibrillators (CRT-D) to treat patients with heart failure. The newest additions to the Attain Performa lead portfolio, the S-shape and Straight leads, are designed to accommodate patients' varying vessel sizes and curvatures to enhance successful lead placement. Quadripolar leads (leads with four electrodes) help physicians optimize cardiac resynchronization therapy, which uses an implantable device to improve the pumping efficiency of the heart. FDA approval for the additional quadripolar leads follows the August 2014 approval of the Attain Performa Model 4298 Dual Cant quadripolar lead. All three leads were studied in the multicenter Attain Performa Quadripolar. Lead Clinical Study, involving more than 1,200 patients. Results featured at the 2014 American Heart Association Scientific Session demonstrate an excellent implant success rate (97.6 percent), and show that CRT with the Attain Performa family of LV quadripolar leads is associated with a low complication rate, and low, stable pacing capture thresholds (PCTs) through six months for all pacing polarities. The three Attain Performa lead shapes -Dual Cant Model 4298, Straight Model 4398 and S-Shape Model 4598 –were designed to accommodate various anatomies without compromising lead handling or stability. With 16 pacing configurations and shorter spacing between the two center electrodes, these quadripolar leads have been shown to reduce the incidence of phrenic nerve stimulation (PNS), a potential issue associated with CRT therapy that results in muscle twitching, hiccups or shortness of breath.ii Attain Performa leads also include steroid elution on all four electrodes for lower chronic pacing thresholds, which contribute to greater device longevity and reduce the likelihood of PNS.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDT*:MM $1,065.00 MXN -38.00

MDT* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $211.95 USD +1.83
Astellas Pharma Inc ¥1,725 JPY +11.50
Becton Dickinson and Co $139.34 USD -0.56
Covidien PLC $103.21 USD -0.14
Stryker Corp $95.64 USD -0.36
View Industry Companies
 

Industry Analysis

MDT*

Industry Average

Valuation MDT* Industry Range
Price/Earnings 25.4x
Price/Sales 4.2x
Price/Book 3.7x
Price/Cash Flow 22.2x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDTRONIC INC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.